Breakthrough research into one of the world’s oldest medicines could lead to new anti-cancer medicines.
Ancient Egyptians first used salicylate, extracted from willow bark, but it was not until the 1890s that it was developed into aspirin (acetyl salicylate).
But now, Professor Grahame Hardie from the University of Dundee, Scotland, UK, has discovered that salicylate switches on the enzyme AMP-activated protein kinase (AMPK), which acts as a molecular switch that inhibits cell growth and has many effects on metabolism.
Writing in the journal Science, Prof Hardie says that some of the metabolic effects of salicylate are mediated by AMPK.
His study raises the possibility that some benefits of aspirin, including the prevention of blood clots that might lead to heart attacks and strokes, and protection against cancer, could be as a result of AMPK.
Professor Hardie said another Dundee study, carried out in 2005 by Professor Andrew Morris, found that that the diabetes drug metformin, which also switches on AMPK, is another drug that provides protection against cancer.
“If we can prove that the anti-cancer effects are mediated by AMPK, then other salicylate-based drugs, with fewer side effects than aspirin, might perhaps be used instead,” he explained.
“We have shown that, unlike other aspirin targets, AMPK is only affected by salicylate, the breakdown product of aspirin in the body, and not by aspirin itself.
“Aspirin has many beneficial effects but, despite it being used in humans for over 100 years, we are still finding out how they come about.”
The paper was co-authored by Dr Greg Steinberg from McMaster University in Canada. The research was funded by the Wellcome Trust.
The ancient drug salicylate directly activates AMP-activated protein kinase. Hardie G. Science April 20 2012. doi: 10.1126/science.1215327.

Leave a Reply